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Mutations in the gene encoding
the PML nuclear body protein
Sp110 are associated with
immunodeficiency and hepatic
veno-occlusive disease
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We describe mutations in the PML nuclear body protein
Sp110 in the syndrome veno-occlusive disease with
immunodeficiency, an autosomal recessive disorder
of severe hypogammaglobulinemia, combined T and
B cell immunodeficiency, absent lymph node germinal
centers, absent tissue plasma cells and hepatic veno-occlusive
disease. This is the first report of the involvement of a
nuclear body protein in a human primary immunodeficiency
and of high-penetrance genetic mutations in hepatic
veno-occlusive disease.
Hepatic veno-occlusive disease with immunodeficiency syndrome
(VODI, OMIM235550) is an autosomal recessive primary immuno-
deficiency associated with hepatic vascular occlusion and fibrosis1.
VODI has an estimated frequency of 1:2,500 live births in the Sydney
Lebanese population, with 19 cases identified over a period of
30 years. VODI is associated with an 85% mortality if unrecognized
and untreated with intravenous immunoglobulin and Pneumocystis
jerovici prophylaxis. The association of an immunodeficiency with
hepatic veno-occlusive disease (hVOD) has not been recognized in
other classes of immunodeficiency, suggesting that hVOD is not a
secondary event but is a primary feature of VODI.
We identified six children from five families of Lebanese ethnicity
who presented between 3–7 months of age with either a combined T
and B cell immunodeficiency and/or a personal or family history of
hVOD (Table 1) who met the clinical criteria for VODI (see
Supplementary Methods online). The clinical correlates of immuno-
deficiency included Pneumocystis jerovici infection, enteroviral infec-
tion or mucocutaneous candidiasis, but there was no evidence of
mycobacterial infection. Hepatic VOD was verified by biopsy in at
least one individual in each sibship and was indistinguishable clinically
and pathologically from the sinusoidal obstruction syndrome
described after hematopoietic stem cell transplantation.
The B cell immunodeficiency was characterized by evolving severe
hypogammaglobulinemia, absent memory (CD19+ CD27+ IgD–)
B cells and tonsillar lymph nodes, and circulating CD19+ B cell
numbers and percentages within the normal range. Absence of lymph
node germinal centers and tissue plasma cells have been noted as a
consistent finding in autopsies that have been reported on 12 affected
individuals, consistent with a block in B cell differentiation (M.W.,
personal communication). The T cell immunodeficiency was char-
acterized by reduced numbers of memory (CD4+ CD45RO+ CD27–)
T cells (1–2%; normal is 440%) and low or reduced intracellular
T cell cytokine expression (IFNg, 14% (reference range, 2530%);
IL2, 1–3% (12–32%); IL4 1–2% (4–7%) and IL10 1–2% (1–6%)) after
stimulation with phorbol myristate acetate (PMA) and ionomycin.
CD4 and CD8 T cell numbers and percentages and T cell proliferation
assays were normal.
We performed homozygosity mapping in four affected individuals
and their parents from families A, B and C after obtaining approval
from the relevant institutional ethics committees and informed
written consent. We mapped VODI to chromosome 2q36.3-37.1.
Fine-mapping studies identified a conserved haplotype of three
short tandem repeat (STR) markers spanning a genomic interval
of 1.422 Mb (Fig. 1a,b) that contained the gene SP110 (encoding
110-kDa Speckled). SP110 is an immunoregulatory gene expressed in
T and B lymphocytes, lymph nodes, spleen and liver2,3; therefore, we
screened its coding exons for mutations by DNA sequencing.
Mutation screening (Supplementary Table 1 and Supplementary
Methods) identified a homozygous single-base deletion, 642delC
(P214PfsX15), in exon 5 in affected individuals from families A–C
and subsequently in family D (Fig. 1c). No living affected individuals
were available from family E, but the consanguineous parents and
unaffected children were shown to share a heterozygous single-base
deletion, 40delC (Q14SfsX25) in exon 2 on a different haplotype
background from families A–D. We confirmed that this mutation was
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homozygous in DNA extracted from archival tissue from EII.1. We did
not detect either mutation in 50 unrelated Lebanese controls. In
addition, we did not detect any mutations in the coding regions of
SP110 in 89 isolated cases of common variable immunodeficiency of
European or Middle Eastern origin4.
Sp110 nuclear staining was absent in EBV-transformed B lympho-
cytes from an affected individual with the homozygous 642delC
mutation in exon 5. Sp100 staining was consistent with normal
PML nuclear body numbers (Fig. 2a–h). Protein blot analysis using
a rat anti-Sp110 antiserum confirmed the absence of the two major
isoforms, Sp110b and Sp110c, in affected cell lines (Fig. 2i). A
quantitative TaqMan real-time PCR assay demonstrated significantly
reduced SP110 mRNA levels in B lymphoblastoid cell lines established
from 642delC homozygous patients compared with their heterozygous
siblings and familial controls (Fig. 2j). We did not see any corre-
sponding changes in mRNA levels in the evolutionarily related,
physically adjacent genes SP100 and SP140. Long-range PCR per-
formed on random hexamer-primed cDNA generated from indivi-
duals with VODI and heterozygotes showed no evidence of exon
skipping (data not shown). These data are consistent with absence of
Sp110 without disruption of the PML nuclear body in individuals
with VODI.
Given the association between mutations in SP110 and hVOD,
we were interested to determine if there was an association between
Sp110 alleles and the risk of hVOD after hematopoietic stem cell
transplantation. We performed a targeted SP110 SNP association
study using 69 SNPs with an average inter-
SNP distance of 0.826 kb in a cohort of 47
affected individuals and 62 controls who had
received standardized myeloablative condi-
tioning therapy5. Measures of association
between hVOD and alleles of SP110 did not
reach statistical significance.
Table 1 Summary of clinical and laboratory data in the VODI families
Age
Serum Ig (g l–1)
Percentage
circulating
cells
Memory T T cell PHA/ConA
T cell
cytokine
Individual Sex (months) Presentation IgM IgG IgA B T & B cells subsets Response production Current clinical state
A II.1 F 5 Immunodeficiency,
thrombocytopenia
and hVOD
0.16 0.5 o0.07 N N – N N – Deceased; recurrent hVOD
post HSCT
B II.1 M 7 Immunodeficiency 0.1 0.2 0.07 N N Decreased N N Impaired Well
B II.2 F 6 Hepatosplenomegaly
and ascites
0.09 o0.33 o0.07 17 58 Decreased N N Impaired Mild aminotransferase
elevation
C II.1 F 4 Hepatosplenomegaly
and thrombocytopenia
0.2 0.55 o0.07 8 79 Decreased N N Impaired Chronic liver disease and
portal hypertension
D II.1 M 3 hVOD 0.05 o0.33 o0.07 23 79 Decreased N N Impaired Deceased; hemophagocytic
syndrome post hepatic
transplant for hVOD
E I.1 M 3 Immunodeficiency &
thrombocytopenia
0.05 0.8 o0.06 N N – N N – Deceased; enteroviral
and Pneumocystis jerovici
infection
PHA: phytohemagglutinin; ConA: concanavalin A; HSCT: hematopoietic stem cell transplantation.
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Figure 1 SP110 mapping and mutation analysis.
(a) Pedigree structure and haplotypes in the
region 2q37.1 for five families with VODI. The
shaded haplotype shared by affected family
members is oriented with centromere towards the
top of the page. Individuals II.1 and II.2 in family
C and individual II.1 family B show the position
of the centromeric and telomeric crossover
events. ‘na’ in families D and E indicates an STR
that was not analyzed. (b) Gene and STR
localizations within the minimal critical region.
(c) Partial SP110 DNA sequences for exons 5
(forward) and 2 (reverse) in normal controls,
affected individuals and heterozygotes. The
reference sequence used is GenBank accession
number NM_080424, with base 1 assigned to
the initiator ATG in exon 2.
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SP110, an SP100 gene family member with three isoforms, encodes
a 713-residue protein that has structural features consistent with a role
in transcriptional regulation, including a nuclear localization signal;
SP100-like dimerization, plant homeobox, bromo and LXXLL-type
nuclear hormone domains and Sp100/AIRE-1/NucP41/75 domains
(SAND)6,7. Sp110 can also increase transcriptional activity from
retinoic acid response elements by binding to the retinoic acid
receptor a (RARa), whereas the Sp110b isoform binds RARa and
acts as a transcriptional corepressor7. Sp110 is associated with the
PML nuclear body, a macromolecular complex within the nucleus that
is deployed to areas of active host or viral DNA replication, transcrip-
tion and repair8–10. In addition to the regulation of gene transcription,
the PML nuclear body is involved in other cellular processes such as
apoptosis, cell cycle control and the immune response. Our data are
consistent with Sp110 having an important role in the immune
response without being essential for PML nuclear body formation.
This study also extends previous findings on the role of the mouse
SP110 orthologue, Ifi75, in the increased susceptibility to mycobacter-
ial and listerial infections in C3HeB/FeJ inbred strain of laboratory
mice11. Full-length transcripts of Ifi75 are absent in C3HeB/FeJ. No
abnormalities of T cell function, alveolar B cell numbers or expression
of CD19, B220 or CD69 have been reported in C3HeB/FeJ. There is
also no evidence of hVOD in this strain; however, this was assessed in
the context of mycobacterial infection rather than bone marrow
ablative therapy (I. Kramnik, personal communication). Notably, the
full characterization of the C3HeB/FeJ Ifi75 genomic region, including
the genomic basis of the lack of full-length Ifi75 expression, has yet to
be defined. The discordance in the phenotypes observed in humans
and mice may be related to different muta-
tional bases of disruption of SP110 and Ifi75
in the two species. Phenotypic variation due
to allelic heterogeneity has numerous prece-
dents12,13. Alternatively, the variation in
immune phenotype may reflect species-spe-
cific differences, as has been previously docu-
mented for the ZAP70 and ICOS genes14,15.
In summary, this study indicates that SP110
has an important role in immunoprotective
mechanisms against infectious organisms in
humans. VODI presents with a T cell abnorm-
ality and a defect in B cell differentiation bet-
ween the stages of CD19 sIg-positive mature
B cells and antibody secreting plasma cells,
with resulting severe hypogammaglobuline-
mia. The failure of T cells from affected in-
dividuals to express IFNg, IL2 and IL4 and the
expression of low levels of IL10 in response to
PMA and ionomycin stimulation suggest
either the abolition of transcriptional coacti-
vation of these genes by SP110 or an effect
secondary to a block in B cell maturation. The
mechanisms by which mutations in SP110
lead to decreased T cell cytokine production,
the failure of B cell differentiation and sinu-
soidal injury have yet to be elucidated. We
hypothesize that SP110 not only has a role in
interferon-dependent transcription of genes
central to cytokine production and lympho-
cyte differentiation but that it is also involved
in cytoprotection. This represents the first
report of a human immunodeficiency syn-
drome associated with mutations in a nuclear body protein and the
identification of the molecular basis of a mendelian form of hVOD.
Note: Supplementary information is available on the Nature Genetics website.
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Figure 2 Functional consequences of SP110 mutations. (a–h) Indirect immunofluorescence analysis of
Sp110 expression with a rat anti-human Sp110 polyclonal antiserum showing absent Sp110 nuclear
staining and the presence of normal Sp100 nuclear body staining in an affected individual. Also shown
are images of DAPI staining, demonstrating nuclear localization. (i) Protein blot showing absence of
Sp110 expression in EBV-transformed B cells from a homozygous affected individual versus a normal
control. (j) Relative mRNA levels of total SP110, SP110b, SP110c, SP140 and SP100 in affected
individuals (n ¼ 4) and a carrier (normalized to expression from a control individual ± 1 s.d.).
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